Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

Bristol Myers Squibb (BMS) has received approval from the European Commission (EC) for its CD19-directed CAR T cell therapy ...

For your long-term dollars, here's my suggestion: the Schwab U.S. Dividend Equity ETF ( SCHD 1.28%). (Remember that an ...

Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of ...

Adults taking the novel once-daily oral pill for plaque psoriasis had significantly higher rates of clear or almost clear ...

The European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

A potential rally to 6,000 is possible if retail sales are positive and the FOMC Meeting is dovish. Read why investors should ...

John Vaughan, a dedicated leader at Verily Life Sciences LLC, serves in multiple roles including lead product counsel, ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other Friday’s worst performing stocks. Wall Street’s main indices bounced back on Friday, ...